Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

Obesity pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.

ClassNone selected
MechanismNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

299 of 2118 arms with a reported figure. Choose arms to narrow the chart.

Efficacy against discontinuation

Change in body weight, %. Discontinued for adverse events, %.

Source: Cited trial source. An arm needs both figures at the same timepoint.

Y axis: Discontinued for adverse events, %

50Semaglutide 7.2 mgSemaglutide 7.2 mg, -18.8, 5.4%Semaglutide PlaceboSemaglutide Placebo, -3.9, 1%

X axis: Change in body weight, %

Show as table
ArmChange in body weight, %Discontinued for adverse events, %
Semaglutide 7.2 mg-18.85.4%
Semaglutide Placebo-3.91%

Not shown

  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Semaglutide placebo: no arm n for percent
  • Semaglutide 2.4 mg: no arm n for percent
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo (semaglutide): endpoint not reported
  • Semaglutide 1.0 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Semaglutide placebo I/II: endpoint not reported
  • Semaglutide Semaglutide: no arm n for percent
  • Semaglutide Placebo: no arm n for percent
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo, in trial: endpoint not reported
  • Semaglutide 15 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Semaglutide placebo OW: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Semaglutide placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo, in trial: endpoint not reported
  • Semaglutide Insuline glargine U100 (reduced) + semaglutide: endpoint not reported
  • Semaglutide Insuline glargine U100 (titrated): endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo (semaglutide): endpoint not reported
  • Semaglutide 7.2 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide 1.7 mg: endpoint not reported
  • Semaglutide 1.7 mg: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo (semaglutide): endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo, in trial: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo (semaglutide): endpoint not reported
  • Semaglutide Semaglutide: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported
  • Semaglutide Placebo: endpoint not reported
  • Semaglutide Semaglutide, on treatment: endpoint not reported
  • Semaglutide Placebo, on treatment: endpoint not reported
  • Tirzepatide Placebo: no arm n for percent
  • Tirzepatide 5 mg: no arm n for percent
  • Tirzepatide 10 mg: no arm n for percent
  • Tirzepatide 15 mg: no arm n for percent
  • Tirzepatide 15 mg: endpoint not reported
  • Tirzepatide Placebo: endpoint not reported
  • Tirzepatide 10 mg: endpoint not reported
  • Tirzepatide Tirzepatide (lead-in): endpoint not reported
  • Tirzepatide Tirzepatide MTD: endpoint not reported
  • Tirzepatide Placebo: endpoint not reported
  • Tirzepatide Tirzepatide: endpoint not reported
  • Tirzepatide Placebo: endpoint not reported
  • Tirzepatide Tirzepatide: endpoint not reported
  • Tirzepatide Placebo: endpoint not reported
  • Tirzepatide Tirzepatide MTD_GPI1: endpoint not reported
  • Tirzepatide Placebo_GPI1: endpoint not reported
  • Tirzepatide Tirzepatide MTD_GPI2: endpoint not reported
  • Tirzepatide Placebo_GPI2: endpoint not reported
  • Tirzepatide 15 mg: endpoint not reported
  • Tirzepatide Placebo: endpoint not reported
  • Tirzepatide 10 mg: endpoint not reported
  • Tirzepatide 15 mg: endpoint not reported
  • Tirzepatide Placebo: endpoint not reported
  • Tirzepatide 10 mg: endpoint not reported
  • Orforglipron Placebo: endpoint not reported
  • Orforglipron 6 mg: endpoint not reported
  • Orforglipron 12 mg: endpoint not reported
  • Orforglipron Placebo QD: endpoint not reported
  • Orforglipron 6 mg: endpoint not reported
  • Orforglipron 12 mg: endpoint not reported
  • Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg: no arm n for percent
  • Cagrilintide/semaglutide Placebo s.c.: no arm n for percent
  • Retatrutide 4 mg: no arm n for percent
  • Retatrutide 9 mg: no arm n for percent
  • Retatrutide 12 mg: no arm n for percent
  • Retatrutide Placebo: no arm n for percent
  • Survodutide 3.6 mg: no arm n for percent
  • Survodutide 6.0 mg: no arm n for percent
  • Survodutide Placebo: no arm n for percent
  • Survodutide 0.6 mg: endpoint not reported
  • Survodutide Placebo group: endpoint not reported
  • Survodutide 2.4 mg: endpoint not reported
  • Survodutide 3.6 mg: endpoint not reported
  • Survodutide 4.8 mg: endpoint not reported
  • VK2735 2.5 mg: no arm n for percent
  • VK2735 15 mg: no arm n for percent
  • VK2735 Placebo 13 weeks: no arm n for percent
  • Eloralintide Placebo: no arm n for percent
  • Eloralintide 1 mg: no arm n for percent
  • Eloralintide 3 mg: no arm n for percent
  • Eloralintide 6 mg: no arm n for percent
  • Eloralintide 9 mg: no arm n for percent
  • Berobenatide Placebo: endpoint not reported
  • Dulaglutide Dulaglutide Arm: endpoint not reported
  • Dulaglutide Placebo Arm: endpoint not reported
  • Exenatide Group A: endpoint not reported
  • Exenatide Group B: endpoint not reported
  • Exenatide Exenatide: endpoint not reported
  • Exenatide Placebo: endpoint not reported
  • Exenatide Exenatide once weekly (EQW ): no arm n for percent
  • Exenatide Dapagliflozin (DAPA): no arm n for percent
  • Exenatide EQW plus DAPA: no arm n for percent
  • Exenatide Dapagliflozin plus Glucophage (MET ER): no arm n for percent
  • Exenatide Phentermine /Topiramate (PHEN/ TPM) ER: no arm n for percent
  • Exenatide Exenatide once weekly extended-release: no arm n for percent
  • Exenatide Matching placebo: no arm n for percent
  • Exenatide Group A: endpoint not reported
  • Exenatide Group B: endpoint not reported
  • Liraglutide 3.0mg: no arm n for percent
  • Liraglutide 3.0mg: no arm n for percent
  • Liraglutide Liraglutide Placebo, no Pre-diabetes: no arm n for percent
  • Liraglutide Liraglutide Placebo, Pre-diabetes: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: no arm n for percent
  • Liraglutide 1.8 mg: no arm n for percent
  • Liraglutide Placebo: no arm n for percent
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide Semaglutide: endpoint not reported
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo (liraglutide): endpoint not reported
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Placebo, in trial: endpoint not reported
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide Metformin XR plus liraglutide: no arm n for percent
  • Liraglutide Metformin XR plus placebo: no arm n for percent
  • Liraglutide Liraglutide Pen Injector (Saxenda): no arm n for percent
  • Liraglutide Placebo liraglutide pen injector: no arm n for percent
  • Liraglutide Liraglutide: endpoint not reported
  • Liraglutide Placebo: endpoint not reported
  • Liraglutide 0.05 mg: endpoint not reported
  • Liraglutide 0.1 mg: endpoint not reported
  • Liraglutide 0.2 mg: endpoint not reported
  • Liraglutide 0.3 mg: endpoint not reported
  • Liraglutide 0.4 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Placebo + Metformin: endpoint not reported
  • Liraglutide Liraglutide + Metformin: endpoint not reported
  • Liraglutide 100 mcg: endpoint not reported
  • Liraglutide 200 mcg: endpoint not reported
  • Liraglutide 300 mcg: endpoint not reported
  • Liraglutide 2.4 mg: endpoint not reported
  • Liraglutide 4.5 mg: endpoint not reported
  • Liraglutide 1.2 mg: endpoint not reported
  • Liraglutide 0.6 mg: endpoint not reported
  • Liraglutide 0.3 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Liraglutide Orlistat: endpoint not reported
  • Lixisenatide Lixisenatide: endpoint not reported
  • Lixisenatide Sitagliptin: endpoint not reported
  • Mazdutide 3/6 Milligrams (mg) Mazdutide: endpoint not reported
  • Mazdutide 10 mg: no arm n for percent
  • Mazdutide 16 mg: no arm n for percent
  • Mazdutide Placebo: no arm n for percent
  • Mazdutide 6 mg: no arm n for percent
  • Oral Semaglutide Oral semaglutide: endpoint not reported
  • Oral Semaglutide Oral semaglutide placebo: endpoint not reported
  • Oral Semaglutide 25 mg: endpoint not reported
  • Oral Semaglutide Oral semaglutide placebo: endpoint not reported
  • Oral Semaglutide 50 mg: endpoint not reported
  • Oral Semaglutide oral semaglutide placebo once daily: endpoint not reported
  • TERN-601 250 mg: endpoint not reported
  • TERN-601 500 mg: endpoint not reported
  • TERN-601 750 mg: endpoint not reported
  • TERN-601 Matching Placebo: endpoint not reported
  • CT-868 CT-868 Placebo: endpoint not reported
  • CT-868 1.8 mg: endpoint not reported
  • CT-868 4.1 mg: endpoint not reported
  • CT-868 6.6 mg: endpoint not reported
  • HM15211 HM15211: endpoint not reported
  • HM15211 Placebo: endpoint not reported
  • Pramlintide Placebo-P + Placebo-M: endpoint not reported
  • Pramlintide 360 mcg: endpoint not reported
  • Pramlintide 5.0 mg: endpoint not reported
  • Pramlintide 2.5 mg: endpoint not reported
  • Pramlintide 5.0 mg: endpoint not reported
  • Pramlintide 1.25 mg: endpoint not reported
  • Pramlintide 2.5 mg: endpoint not reported
  • Pramlintide 5.0 mg: endpoint not reported
  • Pramlintide 1: endpoint not reported
  • Pramlintide 2: endpoint not reported
  • Pramlintide 3: endpoint not reported
  • Pramlintide Placebo: endpoint not reported
  • Pramlintide Pramlintide + Metreleptin: endpoint not reported
  • Pramlintide Pramlintide Acetate and Placebo: endpoint not reported
  • Pramlintide Lead-In Period: endpoint not reported
  • Bimagrumab 30 mg: endpoint not reported
  • Bimagrumab 30 mg: endpoint not reported
  • Bimagrumab 30 mg: endpoint not reported
  • Bimagrumab 1.0 mg: endpoint not reported
  • Bimagrumab 2.4 mg: endpoint not reported
  • Bimagrumab 1.0 mg: endpoint not reported
  • Bimagrumab 2.4 mg: endpoint not reported
  • Naltrexone And Bupropion NB16: endpoint not reported
  • Naltrexone And Bupropion NB32: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion NB32: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion NB32: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion NB32: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion BWL + NB medication: endpoint not reported
  • Naltrexone And Bupropion BWL + Placebo: endpoint not reported
  • Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: endpoint not reported
  • Naltrexone And Bupropion BWL + Placebo: endpoint not reported
  • Naltrexone And Bupropion NB medication: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion Naltrexone+Bupropion Medication: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Naltrexone And Bupropion Naltrexone/Bupropion: endpoint not reported
  • Naltrexone And Bupropion Placebo: endpoint not reported
  • Orlistat Intensive Lifestyle Mod. Intervention: endpoint not reported
  • Orlistat Standard Lifestyle Intervention: endpoint not reported
  • Orlistat Placebo: endpoint not reported
  • Orlistat Orlistat: endpoint not reported
  • Phentermine And Topiramate VI-0521 Low: endpoint not reported
  • Phentermine And Topiramate VI-0521 Top: endpoint not reported
  • Phentermine And Topiramate Placebo: endpoint not reported
  • Phentermine And Topiramate VI-0521 Top: endpoint not reported
  • Phentermine And Topiramate VI-0521 Mid: endpoint not reported
  • Phentermine And Topiramate TPM 46: endpoint not reported
  • Phentermine And Topiramate TPM 92: endpoint not reported
  • Phentermine And Topiramate PHEN 7.5: endpoint not reported
  • Phentermine And Topiramate PHEN 15: endpoint not reported
  • Phentermine And Topiramate Placebo: endpoint not reported
  • Phentermine And Topiramate LSMT 12: endpoint not reported
  • Phentermine And Topiramate LSMT 24: endpoint not reported
  • Phentermine And Topiramate Phentermine & Topiramate: endpoint not reported
  • Phentermine And Topiramate Placebo Drugs: endpoint not reported
  • Phentermine And Topiramate Semaglutide: endpoint not reported
  • Phentermine And Topiramate Other anti-obesity medication: endpoint not reported
  • Setmelanotide Setmelanotide: endpoint not reported
  • Setmelanotide Placebo: endpoint not reported
  • Setmelanotide Setmelanotide: endpoint not reported
  • Setmelanotide Setmelanotide (Double-Blind): endpoint not reported
  • Setmelanotide Placebo (Double-Blind): endpoint not reported
  • Setmelanotide Setmelanotide (Open-label): endpoint not reported
  • Setmelanotide Pivotal Cohort: no arm n for percent
  • Setmelanotide 2 mg: endpoint not reported
  • Setmelanotide 2.5 mg: endpoint not reported
  • Setmelanotide 3 mg: endpoint not reported
  • Setmelanotide 20 mg: endpoint not reported
  • Setmelanotide 25 mg: endpoint not reported
  • Setmelanotide 3 mg: endpoint not reported
  • Setmelanotide 30 mg: endpoint not reported
  • Setmelanotide 20 mg: endpoint not reported
  • Setmelanotide 25 mg: endpoint not reported
  • Setmelanotide 30 mg: endpoint not reported
  • Setmelanotide Setmelanotide: no arm n for percent
  • Setmelanotide Setmelanotide: no arm n for percent
  • Setmelanotide Setmelanotide: PPL Group: endpoint not reported
  • Setmelanotide Setmelanotide: BBS Group: endpoint not reported
  • Setmelanotide 16p11.2 Cohort: endpoint not reported
  • Setmelanotide AS Cohort: endpoint not reported
  • Setmelanotide BBS Cohort: endpoint not reported
  • Setmelanotide MC4R Cohort: endpoint not reported
  • Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort: endpoint not reported
  • Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort: endpoint not reported
  • Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort: endpoint not reported
  • Setmelanotide SH2B1 Cohort: endpoint not reported
  • Setmelanotide SMS Cohort: endpoint not reported
  • Setmelanotide SRC1 Cohort: endpoint not reported
  • Setmelanotide Stage 1: Setmelanotide (Open-Label): no arm n for percent
  • Setmelanotide Stage 2: Setmelanotide (Double-Blind): endpoint not reported
  • Setmelanotide Stage 2: Placebo (Double-Blind): endpoint not reported
  • Setmelanotide Placebo: endpoint not reported
  • Setmelanotide Setmelanotide: endpoint not reported
  • Setmelanotide Placebo: endpoint not reported
  • Setmelanotide 0.5 mg: endpoint not reported
  • Setmelanotide 1.5 mg: endpoint not reported
  • Setmelanotide 2.5 mg: endpoint not reported
  • Setmelanotide Placebo: endpoint not reported
  • Sibutramine Sibutramine: endpoint not reported
  • Sibutramine Placebo: endpoint not reported
  • Tesofensine placebo arm: endpoint not reported

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.